Tarsus Pharmaceuticals, Inc. (TARS) Q3 2021 Earnings Results

Tarsus Pharmaceuticals Misses on EPS — Stock Down 1.5%

Tarsus Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a 1.5% decline in stock price. The lack of revenue figures and guidance indicates uncertainty about the company's near-term performance. Investors may be cautious as management navigates current challenges without clear direction for the future.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.76	N/A	-17.83%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concern over current performance but highlighted efforts to enhance operations. They did not provide specific guidance for future quarters.

Management acknowledged the challenges faced during the quarter.

They emphasized ongoing efforts to improve operational efficiency.

Future prospects were discussed, but no specific guidance was provided.

Tarsus Pharmaceuticals Misses on EPS — Stock Down 1.5%

Key numbers

Management commentary

Tarsus Pharmaceuticals, Inc.

More earnings this week

Tarsus Pharmaceuticals Misses on EPS — Stock Down 1.5%

Key numbers

Management commentary